Barclays’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,412
| Closed | -$1.84K | – | 5462 |
|
|
2025
Q2 | $1.84K | Sell |
1,412
-28,826
| -95% | -$34.7K | ﹤0.01% | 5042 |
|
|
2025
Q1 | $42K | Sell |
30,238
-13,243
| -30% | -$29K | ﹤0.01% | 4663 |
|
|
2024
Q4 | $99.6K | Buy |
43,481
+4,009
| +10% | +$10.6K | ﹤0.01% | 4594 |
|
|
2024
Q3 | $107K | Buy |
39,472
+30,095
| +321% | +$73.5K | ﹤0.01% | 4555 |
|
|
2024
Q2 | $21.9K | Sell |
9,377
-8,551
| -48% | -$27.3K | ﹤0.01% | 4424 |
|
|
2024
Q1 | $84.1K | Sell |
17,928
-15,465
| -46% | -$80.3K | ﹤0.01% | 4495 |
|
|
2023
Q4 | $163K | Buy |
33,393
+27,938
| +512% | +$116K | ﹤0.01% | 4498 |
|
|
2023
Q3 | $25.4K | Buy |
5,455
+1,840
| +51% | +$10.6K | ﹤0.01% | 4116 |
|
|
2023
Q2 | $26.7K | Sell |
3,615
-4,364
| -55% | -$29.1K | ﹤0.01% | 4075 |
|
|
2023
Q1 | $65.3K | Buy |
7,979
+3,744
| +88% | +$39.1K | ﹤0.01% | 4358 |
|
|
2022
Q4 | $40.5K | Buy |
4,235
+3,566
| +533% | +$43.9K | ﹤0.01% | 4620 |
|
|
2022
Q3 | $8K | Sell |
669
-5,982
| -90% | -$78.8K | ﹤0.01% | 4377 |
|
|
2022
Q2 | $85K | Sell |
6,651
-1,387
| -17% | -$14.4K | ﹤0.01% | 3832 |
|
|
2022
Q1 | $88K | Buy |
+8,038
| New | +$93.2K | ﹤0.01% | 3843 |
|
Barclays's AKYA Position: Q3 2025 in Review
Barclays sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 1,412 shares — an estimated $1.84K sold.
Barclays first reported a position in AKYA in Q1 2022 and held it in 14 quarters. The position peaked at $163K in Q4 2023. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- Barclays reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- Barclays sold 1,412 Akoya BioSciences shares in Q3 2025, an estimated $1.84K.
- Barclays first reported a position in Akoya BioSciences in Q1 2022 and held it in 14 quarters.
- Barclays's Akoya BioSciences position peaked at $163K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.